• Home
  •  / Matinas BioPharma

Matinas BioPharma

OverviewSuggest Edit

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on the development of MAT9001, a candidate for the treatment of cardiovascular and metabolic conditions. The medication is an omega-3 fatty acid-based composition, comprised of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DPA), designed to overcome the shortcomings seen from other agents in the omega-3 class. In addition, the company develops MAT2203, a formulation of Amphotericin B designed to treat invasive fungal infections.
TypePublic
Founded2011
HQBedminster, NJ, USMap
Websitematinasbiopharma.com
Overall CultureD+More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2020)21(+40%)
Revenue (FY, 2019)$89.8 K(-25%)
Share Price (Feb 2021)$1.4 (+19%)
Cybersecurity ratingBMore

Key People/Management at Matinas BioPharma

Jerome D. Jabbour

Jerome D. Jabbour

Chief Executive Officer
Herbert Conrad

Herbert Conrad

Chairman of the Board
Theresa Matkovits

Theresa Matkovits

Chief Development Officer
Patrick G. Lepore

Patrick G. Lepore

Vice Chairman
Raphael J. Mannino

Raphael J. Mannino

Chief Scientific Officer
Keith A. Kucinski

Keith A. Kucinski

Chief Financial Officer
Show more

Matinas BioPharma Office Locations

Matinas BioPharma has offices in Bedminster and Raritan
Bedminster, NJ, US (HQ)
1545 US-206 #302
Raritan, NJ, US
1025 US-202 206, 3rd floor
Show all (2)

Matinas BioPharma Financials and Metrics

Matinas BioPharma Revenue

Matinas BioPharma's revenue was reported to be $89.81 k in FY, 2019
USD

Revenue (Q3, 2020)

95.8k

Net income (Q3, 2020)

(5.4m)

EBIT (Q3, 2020)

(5.6m)

Market capitalization (8-Feb-2021)

285.5m

Closing stock price (8-Feb-2021)

1.4

Cash (30-Sept-2020)

7.1m

EV

282.3m
Matinas BioPharma's current market capitalization is $285.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

194.5k149.7k119.8k89.8k

General and administrative expense

5.3m4.8m4.3m7.6m8.0m7.8m

R&D expense

5.2m5.3m3.9m9.0m6.8m11.2m

Operating expense total

10.5m10.1m8.3m16.7m14.8m19.0m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

59.9k15.0k44.9k44.9k29.9k89.8k89.8k95.8k

General and administrative expense

1.1m1.3m1.5m1.2m1.1m1.3m1.3m977.7k999.8k2.1m1.7m1.4m2.0m2.0m1.6m1.8m1.8m1.9m2.3m2.4m2.4m

R&D expense

1.1m1.1m1.1m1.4m1.4m879.2k921.7k642.6k835.3k2.4m2.3m2.0m2.2m1.5m1.4m2.3m2.8m2.7m4.1m3.4m3.3m

Operating expense total

2.1m2.4m2.6m2.6m2.5m2.2m2.2m1.6m1.8m4.5m4.0m3.5m4.2m3.5m3.0m4.1m4.6m4.6m6.3m5.8m5.7m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

2.6m3.2m4.1m7.3m12.4m22.2m

Prepaid Expenses

114.4k231.8k304.4k502.0k538.6k1.9m

Current Assets

2.8m3.6m4.6m8.0m13.1m29.9m

PP&E

340.0k377.7k356.1k1.6m2.0m1.7m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

8.6m6.6m5.0m4.6m6.6m4.4m1.7m578.3k6.2m15.8m11.3m9.0m4.3m8.9m6.6m39.4m36.8m32.7m10.1m14.9m7.1m

Accounts Receivable

89.8k

Prepaid Expenses

87.6k38.1k108.1k93.6k115.0k342.2k138.0k139.6k254.0k803.0k317.3k1.0m475.3k249.8k692.4k391.0k494.6k1.4m2.7m1.1m2.2m

Current Assets

8.6m6.7m5.1m4.8m6.9m4.9m1.9m773.5k6.5m16.8m11.7m10.2m4.9m9.3m7.5m39.9m37.4m34.3m74.0m69.2m65.2m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(10.2m)(9.1m)(7.6m)(15.5m)(14.1m)(17.4m)

Depreciation and Amortization

41.6k43.5k52.6k100.6k218.3k206.0k

Accounts Payable

(125.6k)(73.7k)(22.2k)107.3k(287.2k)383.7k

Cash From Operating Activities

(8.0m)(7.8m)(6.1m)(11.5m)(10.3m)(14.1m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(2.1m)(4.6m)(7.2m)(2.6m)(5.0m)(7.1m)(2.2m)(3.9m)(5.7m)(4.5m)(8.5m)(11.9m)(4.1m)(7.5m)(10.5m)(4.1m)(7.4m)(11.8m)(5.0m)(10.7m)(16.1m)

Depreciation and Amortization

9.5k19.9k51.5k10.9k20.6k32.7k12.9k26.3k40.0k12.0k24.8k56.2k47.1k100.1k156.6k47.9k96.9k148.9k57.6k115.4k173.2k

Accounts Payable

(154.4k)(115.7k)(184.9k)(104.9k)174.0k(289.5k)122.7k(22.0k)(288.4k)771.9k(22.4k)(134.0k)(109.4k)(85.5k)(279.4k)99.0k252.5k390.1k274.0k(184.7k)(306.2k)

Cash From Operating Activities

(2.1m)(3.9m)(5.5m)(2.3m)(4.5m)(6.7m)(1.5m)(2.6m)(4.0m)(3.0m)(6.8m)(9.5m)(2.8m)(5.1m)(7.7m)(3.0m)(5.1m)(9.2m)(4.7m)(7.8m)(13.1m)
show all
USDQ1, 2014

Financial Leverage

1.1 x
Show all financial metrics

Matinas BioPharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

Learn more about our premium products
SecurityScorecard logo

Matinas BioPharma Online and Social Media Presence

Matinas BioPharma's Trends

Embed Graph

Matinas BioPharma Company Culture

  • Overall Culture

    D+

    63/100

  • CEO Rating

    C-

    67/100

  • Compensation

    C-

    62/100

  • Diversity

    D

    60/100

Learn more on Comparably

Matinas BioPharma News and Updates

February 01, 2021

Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®

– LYPDISO™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa® –
January 06, 2021

Matinas BioPharma to Present at the ICR Conference 2021

BEDMINSTER, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the ICR Conference 2021 on Thursday, January 14, 2021 at 1:00 p.m. ET.
December 07, 2020

Thinking about buying stock in Affimed NV, Kura Oncology, Matinas BioPharma, Uranium Energy, or Senseonics Holdings?

NEW YORK, Dec. 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AFMD, KURA, MTNB, UEC, and SENS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
December 07, 2020

Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platform Delivery Technology

BEDMINSTER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced that they p…
December 07, 2020

Matinas BioPharma Files Preliminary Proxy for Special Meeting of Stockholders

- Special Meeting of Stockholders Scheduled for January 26, 2021 Seeking Authorization to Potentially Effectuate a Discretionary Reverse Stock Split Prior to January 26, 2022 -
December 01, 2020

Matinas BioPharma Appoints Hui Liu, Ph.D., M.B.A. as Chief Technology Officer

– Dr. Liu brings more than 20 years of expertise in pharmaceutical development, formulation, and CMC, with specific focus on lipid-based delivery of complex molecules – – Dr. Liu brings more than 20 years of expertise in pharmaceutical development, formulation, and CMC, with specific focus on lipid-…
Show more

Matinas BioPharma Blogs

January 04, 2021

Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001

BEDMINSTER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced the U.S. Fo…
November 19, 2020

Matinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference

BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, has been invited to partici…
November 06, 2020

Matinas BioPharma Reports Third Quarter 2020 Financial Results and Operational Highlights

EnACT study of MAT2203 in cryptococcal meningitis received unanimous Data and Safety Monitoring Board (DSMB) recommendation to proceed into second patient cohort – ENHANCE-IT study of MAT9001 against Vascepa® fully enrolled with topline data anticipated Q1 2021; Phase 3 program on track to initiate…

 Matinas BioPharma Frequently Asked Questions

  • When was Matinas BioPharma founded?

    Matinas BioPharma was founded in 2011.

  • Who are Matinas BioPharma key executives?

    Matinas BioPharma's key executives are Jerome D. Jabbour, Herbert Conrad and Theresa Matkovits.

  • How many employees does Matinas BioPharma have?

    Matinas BioPharma has 21 employees.

  • What is Matinas BioPharma revenue?

    Latest Matinas BioPharma annual revenue is $89.8 k.

  • What is Matinas BioPharma revenue per employee?

    Latest Matinas BioPharma revenue per employee is $4.3 k.

  • Who are Matinas BioPharma competitors?

    Competitors of Matinas BioPharma include Aimmune Therapeutics, Emisphere Technologies and Phio Pharmaceuticals.

  • Where is Matinas BioPharma headquarters?

    Matinas BioPharma headquarters is located at 1545 US-206 #302, Bedminster.

  • Where are Matinas BioPharma offices?

    Matinas BioPharma has offices in Bedminster and Raritan.

  • How many offices does Matinas BioPharma have?

    Matinas BioPharma has 2 offices.